Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YAZFlex
- Development stage
- Phase 4
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**YAZFlex** is a flexible extended-cycle combined oral contraceptive (COC) containing drospirenone (3 mg), a synthetic progestogen with antimineralocorticoid and antiandrogenic properties, and ethinyloestradiol (20 μg as betadex clathrate), a synthetic estrogen. It prevents pregnancy primarily through ovulation inhibition, cervical mucus thickening, and endometrial changes, while offering additional benefits like reduced menstrual bleeding, less painful periods, and treatment of moderate acne vulgaris via androgen suppression. Developed as a variant of the conventional 24/4 regimen YAZ, it provides dosing flexibility for extended use.[3]
- Brand names
- YAZFlex
- Other names
- YAZ Flex
02
Targets
AR (Adrenergic receptors)ER (Estrogen receptor)MR (Mineralocorticoid receptor)PR (Progesterone receptor)
Beyond the preview
Go deeper on YAZFlex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YAZFlex.